Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
UTD2 is the world's first oral epothilone microtubule inhibitor
Pfizer is likely to show GSK significant competition
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated